Keywords
Eligibility Determination ×
Gastroenterology ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

744 Search results.

Eligibility Hepatitis C, Chronic NCT01544920

- 6/4/20 - 1 form, 2 itemgroups, 17 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755); ODM derived from: https://clinicaltrials.gov/show/NCT01544920

Eligibility Hepatitis C, Chronic NCT01459913

- 6/4/20 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype; ODM derived from: https://clinicaltrials.gov/show/NCT01459913

Eligibility Hepatitis C, Chronic NCT01435226

- 6/4/20 - 1 form, 2 itemgroups, 15 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection; ODM derived from: https://clinicaltrials.gov/show/NCT01435226

Eligibility Hepatitis C, Chronic NCT01371578

- 6/4/20 - 1 form, 2 itemgroups, 19 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection; ODM derived from: https://clinicaltrials.gov/show/NCT01371578

Eligibility Hepatitis C, Chronic NCT00910624

- 6/3/20 - 1 form, 2 itemgroups, 15 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Boceprevir Treatment in Participants With Chronic Hepatitis C Genotype 1 Deemed Nonresponders to Peginterferon/Ribavirin (P05514); ODM derived from: https://clinicaltrials.gov/show/NCT00910624

Eligibility Hepatitis C Virus NCT02265237

- 6/3/20 - 1 form, 2 itemgroups, 13 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered With Ribavirin (RBV) in Adults With Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (AGATE-1); ODM derived from: https://clinicaltrials.gov/show/NCT02265237

Eligibility Hepatitis C Virus NCT01581203

- 6/3/20 - 1 form, 3 itemgroups, 10 items, 1 language
Itemgroups: Criteria, Inclusion Criteria, Exclusion Criteria
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives); ODM derived from: https://clinicaltrials.gov/show/NCT01581203

Eligibility Hepatitis C Virus NCT01391117

- 6/3/20 - 1 form, 2 itemgroups, 14 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
TMC649128HPC1002 - a Trial inGenotype 1 Hepatitis C Virus (HCV) - Infected Participants to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of TMC649128, Alone and Combined With Pegylated Interferon + Ribavirin; ODM derived from: https://clinicaltrials.gov/show/NCT01391117

Eligibility Hepatitis C NCT01273064

- 6/3/20 - 1 form, 2 itemgroups, 40 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders; ODM derived from: https://clinicaltrials.gov/show/NCT01273064

Eligibility Hepatitis C NCT01182298

- 6/2/20 - 1 form, 2 itemgroups, 16 items, 1 language
Itemgroups: Criteria, Exclusion Criteria
Open Label Study to Evaluate Chronic Hepatitis C Treatment in Latino Subjects With and Without HIV Co-infection; ODM derived from: https://clinicaltrials.gov/show/NCT01182298

Eligibility Hepatitis C Infection NCT01532908

- 6/2/20 - 1 form, 2 itemgroups, 20 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Open Label Study of the Efficacy and Safety of MBL-HCV1 in Combination With Oral Direct-Acting Antivirals in Patients Undergoing Liver Transplantation for Hepatitis C; ODM derived from: https://clinicaltrials.gov/show/NCT01532908

Eligibility Hepatitis C Virus NCT01193361

- 6/2/20 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Ph IIA Study (SOC +/- NS5B); ODM derived from: https://clinicaltrials.gov/show/NCT01193361